Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease

 Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease

Shots:

  • Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies
  • The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on medical and molecular data sets of thousands of CKD patients
  • The collaboration allows Novo Nordisk to expand its portfolio beyond diabetes targeting the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: Novo Nordisk | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post